MedTrace Logo

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

NCT06057935 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-07-22

No results posted yet for this study

Summary

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.

Conditions

  • Malignant Peritoneal Mesothelioma
  • Peritoneal Mesothelioma
  • Mesothelioma
  • Mesothelioma, Malignant
  • Malignant Mesothelioma

Interventions

DRUG

Pemetrexed

Pemetrexed will be administered intravenously

DRUG

Cisplatin

Cisplatin will be administered intravenously

DRUG

Carboplatin

Possible substitution with carboplatin based on clinician discretion

Sponsors & Collaborators

Principal Investigators

  • Garrett Nash, MD · Memorial Sloan Kettering Cancer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-21
Primary Completion
2028-09-21
Completion
2028-09-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06057935 on ClinicalTrials.gov